Physician profile
Steven Kanter
NPI 1730140922
$19,709.97
in general payments reported to CMS, 2019-2025
77 companies · $3,122 in 2025
The $3,122 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,656 · 2020: $613 · 2021: $2,023 · 2022: $5,039 · 2023: $2,588 · 2024: $4,669 · 2025: $3,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,113 · Consulting Fee: $2,000 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,113.38 |
| Consulting Fee | $2,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Education | $265.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,486.68 | 2019-2025 | Lynparza, Imfinzi, Calquence |
| Tempus Ai, INC | $2,072.90 | 2024-2025 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $1,358.85 | 2019-2025 | Kisqali, Piqray |
| Merck Sharp & Dohme LLC | $1,226.93 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Genentech USA, INC. | $1,020.00 | 2019-2025 | Phesgo, Perjeta, Kadcyla |
| Avyxa Pharma, LLC | $1,000.00 | 2025 | |
| Gilead Sciences, INC. | $563.42 | 2021-2025 | Trodelvy |
| Pfizer INC. | $507.72 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $427.05 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Tg Therapeutics, INC. | $407.20 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $382.34 | 2019-2023 | Imbruvica, Epkinly |
| Celgene Corporation | $350.56 | 2019-2025 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $344.26 | 2019-2024 | Erleada, Darzalex, Tecvayli |
| Amgen INC. | $319.36 | 2019-2023 | Lumakras, Prolia, Evenity |
| Seagen INC. | $305.73 | 2020-2023 | Adcetris, Tukysa, Padcev |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $290.39 | 2019-2025 | Padcev, Xtandi |
| Lilly USA, LLC | $254.31 | 2019-2025 | Verzenio, Jaypirca |
| Abbvie INC. | $252.79 | 2021-2025 | |
| Incyte Corporation | $224.61 | 2021-2025 | Monjuvi, Jakafi |
| Regeneron Healthcare Solutions, INC. | $204.11 | 2021-2025 | Libtayo |
| Genzyme Corporation | $202.84 | 2020-2025 | |
| Emd Serono, INC. | $193.57 | 2019-2025 | Tepmetko, Bavencio |
| Janssen Pharmaceuticals, INC | $185.10 | 2019-2022 | |
| Servier Pharmaceuticals LLC | $170.55 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $168.63 | 2021-2025 | Alunbrig, Iclusig, Fruzaqla |
| Novocure INC. | $158.01 | 2022 | |
| Coherus Oncology, INC. | $148.90 | 2020-2024 | |
| Eisai INC. | $146.64 | 2021-2025 | |
| Daiichi Sankyo INC. | $143.23 | 2022-2025 | Enhertu, Vanflyta |
| Jazz Pharmaceuticals INC. | $132.77 | 2019-2025 | Zepzelca |
| G1 Therapeutics, INC. | $124.97 | 2021-2023 | Cosela |
| Glaxosmithkline, LLC. | $121.15 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Deciphera Pharmaceuticals INC. | $116.14 | 2022-2025 | Qinlock, Romvimza |
| Bayer Healthcare Pharmaceuticals INC. | $111.96 | 2019-2025 | |
| Puma Biotechnology, INC. | $97.98 | 2020-2025 | |
| Beigene USA, INC. | $90.45 | 2020-2025 | Brukinsa, Tevimbra |
| Exelixis INC. | $83.84 | 2019-2024 | Cabometyx |
| Blueprint Medicines Corporation | $82.18 | 2020-2025 | Ayvakit |
| Tersera Therapeutics LLC | $81.86 | 2023-2025 | Xermelo, Zoladex |
| Pharmacosmos Therapeutics INC. | $73.61 | 2022-2024 | Cosela |
| Adaptive Biotechnologies Corporation | $64.53 | 2024-2025 | Clonoseq |
| Mirati Therapeutics, INC. | $64.27 | 2023-2024 | Krazati |
| Cti Biopharma Corp. | $59.10 | 2022-2023 | Vonjo |
| Amag Pharmaceuticals, INC. | $55.35 | 2019-2021 | |
| Inari Medical, INC. | $54.50 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Aveo Pharmaceuticals, INC. | $49.24 | 2022-2024 | Fotivda |
| Agios Pharmaceuticals, INC. | $46.86 | 2024 | Pyrukynd |
| Epizyme, INC. | $38.94 | 2022-2024 | Onivyde |
| Caris Mpi, INC. | $35.58 | 2025 | Mi Cancer Seek |
| Syndax Pharmaceuticals, INC. | $32.44 | 2025 | |
| Tesaro, INC. | $30.89 | 2019 | |
| Immunocore Limited | $30.33 | 2025 | Kimmtrak |
| Stemline Therapeutics INC. | $30.17 | 2023 | Orserdu |
| Karyopharm Therapeutics INC. | $28.92 | 2021 | |
| Verastem, INC. | $28.33 | 2019 | |
| Array Biopharma INC | $28.19 | 2025 | Lorbrena |
| Sobi, INC | $27.47 | 2023 | |
| Accord Healthcare, INC. | $24.98 | 2025 | |
| Morphosys, US INC. | $24.62 | 2021 | |
| Immunogen, INC. | $24.35 | 2024 | Elahere |
| Beone Medicines USA, INC. | $23.17 | 2025 | Brukinsa |
| Fennec Pharmaceuticals, INC. | $22.74 | 2024 | Pedmark |
| Alexion Pharmaceuticals, INC. | $22.68 | 2019 | |
| Siemens Medical Solutions USA, INC. | $19.71 | 2025 | Atellica Ch 930 Analyzer |
| Pharmaessentia USA Corporation | $19.47 | 2024 | Besremi |
| Rigel Pharmaceuticals, INC. | $19.16 | 2024 | Rezlidhia, Tavalisse |
| Clovis Oncology, INC. | $18.91 | 2019 | |
| Genmab U.S., INC. | $17.28 | 2024 | Epkinly |
| Sun Pharmaceutical Industries INC. | $17.05 | 2024 | |
| Amneal Pharmaceuticals LLC | $16.95 | 2023 | Avastin |
| Foundation Medicine, INC. | $16.38 | 2021 | |
| Apellis Pharmaceuticals, INC. | $15.97 | 2022 | |
| Spectrum Pharmaceuticals INC. | $15.77 | 2025 | Rolvedon |
| Sirtex Medical INC | $14.93 | 2022 | |
| Myriad Genetic Laboratories, INC. | $12.98 | 2021 | |
| Acrotech Biopharma INC. | $12.52 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Kanter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.